News | Thrombectomy Devices | January 05, 2017

Global Thrombectomy Devices Market to Exceed $1 Million by 2022

Sedentary lifestyles, rise in geriatric population and demand for more minimally invasive treatments among factors driving market growth

global thrombectomy devices market, Allied Market Research report, 2022

January 5, 2017 — A new report published by Allied Market Research forecasts that the global thrombectomy devices market was valued at $982 million in 2016, and is expected to reach $1.389 million by 2022. This total will be supported by a compound annual growth rate (CAGR) of 5.9 percent during the forecast period 2014 to 2022. Mechanical thrombectomy would continue to be the preferred technology throughout the analysis period. North America dominated with around half of the market share in 2015 and is projected to maintain the lead throughout the forecast period.

High occurrences of acute myocardial infarction, peripheral artery disease, deep vein thrombosis, venous thromboembolism (VTE) and pulmonary embolism owing to sedentary and unhealthy lifestyles majorly drives the market growth, according to the report. VTE is most common in adults >60 years of age. In addition, better healthcare infrastructure and an increase in demand for minimally-invasive treatments; a rise in the geriatric population, which increases incidence of cardiovascular diseases; and technological advancements and innovations are the factors that nurture the growth of the thrombectomy devices market. Some of the restraints associated with the market are scarcity of trained professionals, lack of awareness and the complicated use of devices.

The disposable thrombectomy devices segment generated the highest revenue in 2015 and would continue to follow this trend throughout the analysis period.

Geographically, North America occupied a major market share in 2015, and is expected to continue leading during the analysis period. This was attributed to the sedentary and unhealthy lifestyle of the current generation, demand of better healthcare infrastructure, and increase in demand for minimally-invasive treatments and incidence of cardiovascular diseases. However, Asia-Pacific followed by LAMEA are expected to be the fastest growing regions, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of thrombus.

The thrombectomy devices market holds a substantial scope for growth globally. Recent innovations — which embed introduction of innovative ideas such as use of lasers, ultraviolet radiation and 3-D image generation — will provide better results to the physicians and allow them to work more efficiently. The upcoming trend in this market is the introduction of a technique that involves the combination of decompressive hemicraniectomy and endovascular thrombectomy to treat patients with cerebral venous thrombosis.

Among the other key findings were:

  • Neurovascular disorder is the major indication that uses thrombectomy devices for treatment; with over half of the total market share in 2015;
  • Peripheral and coronary diseases segments are projected to grow at a significant CAGR;
  • Reusable thrombectomy devices is projected to grow at a CAGR of 7.7 percent;
  • The U.S market for thrombectomy devices is projected to grow at a CAGR of 5 percent; and
  • The United States was the largest country market in 2015, and is projected to maintain its lead until 2022.

Key players have adopted mergers and acquisitions and product launch as their key strategies in the thrombectomy devices market. This is due to the growth in competition and continuous technological advancements. In July, 2016, Penumbra launched the ACE 68 Reperfusion Catheter for commercial use in the U.S. This catheter uses the latest tracking technology advancements available and delivers maximum aspiration power for extracting thrombus in stroke intervention. This product launch is expected to strengthen the product portfolio of Penumbra, a leading market player. The major market players profiled in this report include Boston Scientific Corp., Medtronic Plc, Teleflex Inc., Penumbra Inc., The Spectranetics Corp., AngioDynamics Inc., Terumo Corp., Johnson and Johnson Inc., Stryker Corp. and Vascular Solutions Inc.

For more information: www.alliedmarketresearch.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init